Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Martin Shkreli

What's Behind the Social Media Controversy Surrounding IonQ?

Cryptocurrency enthusiasts may increasingly feel that quantum technology is a threat to the digital token space, but companies like IonQ still face hurdles.

MarketBeat

Martin Shkreli Takes Position In QCLS, Leveraging Microsoft's Optical Computing Roadmap For Bull Case: '$100 Is My Near-Term Target'

Martin Shkreli has announced a strategic investment in Q/C Technologies Inc. (NASDAQ:QCLS), setting a bold near-term price target of $100.

Benzinga

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Martin Shkreli Warns Elizabeth Warren And Zohran Mamdani Policies Would Make US Stock Returns Resemble France, Japan's Dismal Performance

While comparing U.S. equity market returns over the past 35 years with those of France and Japan, investor Martin Shkreli issued a sharp warning regarding the growing influence of progressive lawmakers on the nation’s economy.

Benzinga

'Pharma Bro' Martin Shkreli Begs 'Wannabe' Finance Influencers To Learn Basics As China, Malaysia Crack Down On 'Finfluencers'

Martin Shkreli, the former hedge fund manager known as the "Pharma Bro," scolded online finance personalities Thursday after they hunted for alleged red flags in Nvidia Corp.'s (NASDAQ:NVDA) third-quarter financial statements, saying many don't grasp basic accounting.

Benzinga

Ron DeSantis Slams 'Too Big To Fail' Label For OpenAI: The Company 'Hasn't Yet Turned A Profit' Amid Deep Ties To Big Tech

Gov. Ron DeSantis (R) expressed concerns regarding OpenAI’s critical importance to the economy and the broader tech ecosystem.

Benzinga

Martin Shkreli Blasts Trump's Move To Buy Shares Of Quantum Computing Companies For the US Government, Suggests The President Should Do This Instead

Investor Martin Shkreli, popularly known as “Pharma Bro,” is criticizing President Donald Trump’s latest decision to acquire equity stakes in quantum computing stocks.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What's Driving Beyond Meat's 19% Pre-Market Drop? (CORRECTED)

Editor’s note: The story has been corrected to reflect Beyond Meat’s correct trading volume on Wednesday and the pre-market movement on Thursday.

Benzinga

Latest Beyond Meat Short-Seller? Martin Shkreli, Of Course

Beyond Meat, Inc. (NASDAQ:BYND) shares ripped higher on Wednesday as traders discussed a possible "short-squeeze" due to outsized short interest in the stock.

Benzinga

Quantum Stock Tracker: Early Rally Fades, Rigetti And D-Wave Still Up On The Week

Quantum stocks pulled back on Thursday and Friday after a strong rally earlier in the week. Here's a look at what drove the early rally and the pull-back that followed.

Benzinga

Quantum Stock Rally Leaves Shkreli's Short 'Pretty F***n' Far From Okay'

Martin Shkreli, known for his outspoken views in finance, has been shorting quantum computing stocks IonQ, Inc. (NYSE:IONQ), D-Wave Quantum, Inc. (NYSE:QBTS), Rigetti Computing, Inc. (NASDAQ:RGTI), and Quantum Computing Inc. (NASDAQ:QUBT), regularly mocking what he sees as overvaluation and questionable business models.

Benzinga

'Pharma Bro' Martin Shkreli Says Tesla Haters Suffer From 'Common' Delusions: 'TSLAQ' Community Will Require 'Lifelong Institutionalization'

Investor Martin Shkreli, popularly referred to as the “Pharma Bro,” has once again criticized investors who are bearish on Tesla Inc. (NASDAQ:TSLA), even comparing their bets against the electric vehicle giant to several common psychiatric delusions.

Benzinga

Elon Musk 'Won, It's Over': 'Pharma Bro' Defends Tesla Against Short Sellers

Known in the past as the "Pharma Bro" for his ties to the pharmaceutical industry, Martin Shkreli is known these days for shorting individual stocks or entire sectors, like a recent bet against public quantum computing companies.

Benzinga

Diddy wants to serve his time at same low-security prison that housed ‘Pharma Bro’ and influencer ‘Hushpuppi’

The rapper requested to serve time at Fort Dix ‘to address drug abuse issues and to maximize family visitation and rehabilitative efforts’

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Sean 'Diddy' Combs' lawyers want him sent to a New Jersey federal prison that offers drug treatment

Sean “Diddy” Combs’ lawyers want the hip-hop mogul sent to a low-security federal prison in New Jersey to serve his four-year, two-month prison sentence

Benzinga

Martin Shkreli Defends Nvidia-OpenAI Deal: It's A 'Lot More Efficient' This Way — 'Pharma Bro' Cites Growing 'Non-Party Demand'

Investor Martin Shkreli came out in support of the $100 billion investment pledge made by chipmaker NVIDIA Corp. (NASDAQ: NVDA) to ChatGPT-parent OpenAI last week, while arguing that critics are missing the point of how value is created and measured in such partnerships.

Benzinga

'Pharma Bro' Martin Shkreli Mocks IONQ CEO's Nvidia-Sized Ambition: 'Craziest Statement From A CEO I Have Ever Heard'

Investor Martin Shkreli, popularly known as “Pharma Bro,” is once again criticizing quantum computing company, IONQ Inc. (NYSE: IONQ), for comments made by its CEO, Peter Chapman.

Benzinga

Opendoor Is 'Total Garbage,' This Hedge Fund Manager Says: 'The Business Model Does Not Work'

Hedge fund manager George Noble criticized iBuying platform Opendoor Technologies Inc. (NASDAQ:OPEN), which has seen a monumental 1,776% rally since hitting an all-time low in late June.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Martin Shkreli Amplifies Critique Calling D-Wave's Quantum Tech 'Dead-End:' It Would Take Until 2054 To Match Current Classical Solvers

A critique of D-Wave Quantum Inc. (NYSE:QBTS), amplified by ‘Pharma Bro’ Martin Shkreli, is challenging the company’s viability, alleging its technology is a potential “dead-end.”

Benzinga

5 Stocks That Dominated Investor Buzz This Week — How OPEN, NVDA, TSLA And Others Performed

Retail investors buzzed about five stocks this week, from Sept. 15 to 19, on platforms like X and Reddit’s r/WallStreetBets, amid market AI enthusiasm and the Federal Reserve rate cuts.

Benzinga

'Pharma Bro' Martin Shkreli Tells Critics 'Do Not Make Fun of Me' As Opendoor Short Sours Amid Rate-Cut Rally: 'That Is Inappropriate'

Investor Martin Shkreli, popularly known as “Pharma Bro,” pushed back against criticism on this recent short position on iBuying platform Opendoor Technologies Inc. (NASDAQ:OPEN), which is rallying amid the Federal Reserve’s rate cuts on Wednesday.

Benzinga

Jim Cramer Pushes For 'Gone Meme' Stock List As Opendoor Surges, Suggests IonQ's Meme Moment Is Over

CNBC's Jim Cramer called for the creation of a "gone meme list" in a post on the social media platform X on Wednesday, suggesting a need to track companies whose speculative trading frenzy has concluded.

Benzinga

Pharma Bro Martin Shkreli Confirms Shorting Opendoor, Plans Public Due Diligence Campaign Into The Firm: 'I Shorted $OPEN'

Martin Shkreli, also popularly known as ‘Pharma Bro,’ announced late Tuesday that he has taken a short position against iBuying real estate company Opendoor Technologies Inc. (NASDAQ:OPEN).

Benzinga

Anthony Pompliano Says Open Naysayers Should Note New CEO Takes Home $1 Token Pay, Martin Shkreli Counters Company 'Fundamentally Broken'

iBuying platform Opendoor Technologies Inc. (NASDAQ:OPEN) has appointed Kaz Nejatian as its new CEO, who previously served as the COO of Shopify Inc. (NASDAQ:SHOP). His illustrious background and new shareholder-aligned compensation package are being hailed by analysts, investors and even critics alike.

Benzinga

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Former hedge fund manager and pharmaceutical executive, Martin Shkreli, doubled down on his bearish stance against Opendoor Technologies Inc. (NASDAQ:OPEN), drawing parallels with another retail favorite stock that has since witnessed a pullback.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.